clinical trial · NCT05938426
Digital Therapeutics Research on Efficiency About Mild Cognitive Impairment Study
Emocog Inc.·N/A·unknown·n = 100
Mild Cognitive ImpairmentET-101Sham Device
brief summary
The purpose of this study is to evaluate the efficiency and safety of a digital therapeutics(ET-101) for mild cognitive impairment (MCI). This is a randomized, sham-controlled, assessor-blinded, 24-week parallel study. 100 MCI patients will be randomly assigned to two groups. The control group will be provided with a sham device.
started
Jun 8, 2023
primary completion
Mar 31, 2024
completion
Jun 30, 2024
last updated
Feb 23, 2024
official title
Digital Therapeutics (ET-101) Research on Efficiency and Safety About Mild Cognitive Impairment, Randomized, Sham Device, Assessor-blinded, Multi-center Pivotal Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol